NeuroPace (NPCE) Cash from Operations Growth (3y) (2023 - 2026)
NeuroPace (NPCE) Cash from Operations Growth (3y) (2023 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.92 Bn | 146.27 Bn | 6.27 Bn | 4.78% |
| 2 | Stryker | 119.50 Bn | 116.62 Bn | 3.81 Bn | 9.30% |
| 3 | Medtronic | 102.71 Bn | 94.54 Bn | 5.76 Bn | 20.35% |
| 4 | Boston Scientific | 69.72 Bn | 68.51 Bn | 3.61 Bn | 22.35% |
| 5 | Edwards Lifesciences | 49.24 Bn | 45.57 Bn | 1.29 Bn | -48.14% |
| 6 | GE HealthCare Technologies | 29.74 Bn | 27.67 Bn | 1.98 Bn | -14.75% |
| 7 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | 0.50% |
| 8 | Dexcom | 28.96 Bn | 27.84 Bn | 750.30 Mn | 50.11% |
| 9 | Steris | 20.31 Bn | 19.88 Bn | 697.10 Mn | 15.83% |
| 10 | NeuroPace | 534.75 Mn | 480.77 Mn | 18.05 Mn | 15.27% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 15.27% |
| Dec 31, 2025 | 27.32% |
| Sep 30, 2025 | 34.96% |
| Jun 30, 2025 | 41.81% |
| Mar 31, 2025 | 13.01% |
| Dec 31, 2024 | 16.93% |
| Sep 30, 2024 | 26.43% |
| Jun 30, 2024 | 13.44% |
| Mar 31, 2024 | -8.24% |
| Dec 31, 2023 | 19.48% |
| Sep 30, 2023 | 25.38% |
| Jun 30, 2023 | -10.53% |
| Mar 31, 2023 | -14.27% |